Cytosorbents (CTSO) EBT Margin (2011 - 2026)
Cytosorbents (CTSO) posted EBT Margin of 124.55% for Q1 2026, down 109.22% on a QoQ basis from 59.53% in Q4 2025, and down 10761.0% year-over-year from N/an in Q1 2025.
Cytosorbents (CTSO) EBT Margin (2011 - 2026) Analysis & Trends
Cytosorbents' EBT Margin history runs 16 years deep, the most recent figure standing at 124.55% for Q1 2026.
- Quarterly EBT Margin fell 10761.0% year-over-year to 124.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 121.83% (down 10463.0% YoY) and the FY2025 annual result came in at 23.2%, up 682.0% from the prior year.
- EBT Margin was 124.55% for Q1 2026 at Cytosorbents, down from 59.53% in the prior quarter.
- Across five years, EBT Margin topped out at 26.94% in Q4 2024 and bottomed at 262.17% in Q2 2025.
- A 5-year average of 79.75% and a median of 70.07% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin surged 10710 bps — and 2025, when it sank 21359 bps.
- Cytosorbents' EBT Margin stood at 19.79% in 2022, then slumped by 305 bps to 80.16% in 2023, then jumped by 134 bps to 26.94% in 2024, then plunged by 321 bps to 59.53% in 2025, then plunged by 109 bps to 124.55% in 2026.
- Business Quant data shows CTSO's EBT Margin at 124.55% in Q1 2026, 59.53% in Q4 2025, and 37.65% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 18.70% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 27.84% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 22.61% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 4.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.84% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytosorbents | 22.58 Mn | 17.78 Mn | 6.13 Mn | -124.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -124.55% |
| Dec 31, 2025 | -59.53% |
| Sep 30, 2025 | -37.65% |
| Jun 30, 2025 | -262.17% |
| Mar 31, 2025 | -16.94% |
| Dec 31, 2024 | 26.94% |
| Sep 30, 2024 | -32.14% |
| Jun 30, 2024 | -48.58% |
| Mar 31, 2024 | -67.73% |
| Dec 31, 2023 | -80.16% |
| Sep 30, 2023 | -104.28% |
| Jun 30, 2023 | -70.07% |
| Mar 31, 2023 | -77.49% |
| Dec 31, 2022 | -19.79% |
| Sep 30, 2022 | -150.42% |
| Jun 30, 2022 | -128.06% |
| Mar 31, 2022 | -103.16% |
| Dec 31, 2021 | -93.14% |
| Sep 30, 2021 | -65.64% |
| Jun 30, 2021 | -38.90% |